Two Sigma Investments
TRDA icon

Two Sigma Investments’s Entrada Therapeutics TRDA Stock Holding History

Two Sigma Investments’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$563K Sell
44,602
-4,700
-10% -$53.9K ﹤0.01% 3662
2025
Q4 		$507K Sell
49,302
-43,892
-47% -$370K ﹤0.01% 3296
2025
Q3 		$541K Buy
+93,194
New +$545K ﹤0.01% 2947

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments's TRDA Position: Q1 2026 in Review

Two Sigma Investments reduced its Entrada Therapeutics (TRDA) stake by 9.5% in Q1 2026, selling an estimated $53.9K and leaving 44,602 shares worth $563K. The position accounts for ﹤0.01% of the portfolio, ranked #3662.

Two Sigma Investments first reported a position in TRDA in Q3 2025 and has held it in 3 quarters since. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Two Sigma Investments held 44,602 shares of Entrada Therapeutics worth $563K as of Q1 2026.
  • Two Sigma Investments sold 4,700 Entrada Therapeutics shares in Q1 2026, an estimated $53.9K.
  • Entrada Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3662 holding.
  • Two Sigma Investments first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.